Absolute Oral Bioavailability and Disposition of Deferasirox in Healthy Human Subjects-Reference-Cited by-同舟云学术

Absolute Oral Bioavailability and Disposition of Deferasirox in Healthy Human Subjects

Published:2008-08 Issue:8 Volume:48 Page:919-925
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Séchaud Romain,Robeva Anna,Belleli Rossella,Balez Sebastien

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference14 articles.

1. Beta-thalassemia;Rund;N Engl J Med,2005

2. Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine;Aldouri;J Clin Pathol,1987

3. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload;Piga;Haematologica,2006

4. Practical management of iron overload;Porter;Br J Haematol,2001

5. Deferasirox-an oral agent for chronic iron overload;Vanorden;Ann Pharmacother,2006

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of early‐start deferiprone in infants and young children with transfusion‐dependent beta thalassemia: Evidence for iron shuttling to transferrin in a randomized, double‐blind, placebo‐controlled, clinical trial (START);American Journal of Hematology;2023-07-04

2. Non-electrostatic energies as a metric for prediction of deferasirox solubility in binary solvent mixtures: Polarized Continuum Model tactic;Journal of Molecular Liquids;2021-10

3. Effect of Genetic Polymorphisms on the Pharmacokinetics of Deferasirox in Healthy Chinese Subjects and an Artificial Neural Networks Model for Pharmacokinetic Prediction;European Journal of Drug Metabolism and Pharmacokinetics;2020-09-15

4. Use of prior knowledge and extrapolation in paediatric drug development: A case study with deferasirox;European Journal of Pharmaceutical Sciences;2019-08

5. Iron Chelator Deferasirox Reduces Candida albicans Invasion of Oral Epithelial Cells and Infection Levels in Murine Oropharyngeal Candidiasis;Antimicrobial Agents and Chemotherapy;2019-02-04